CRP and cholangiocarcinoma: The dissection of the possible mechanisms behind the protective effects of PUFAs against CC is the subject of several recent reviews [143,144,145,146,147], and the common thread is the acute phase response reduction, with lower serum levels of C-reactive protein (CRP), TNFα, and IL-6, as the main effect underlying the CC prevention.